---
title: "Alaunos Therapeutics surges 14% in after-hours on $1.1M financing deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299495670.md"
description: "TCRT surged 14% after-hours after completing $1.12M offering and amending quorum rules to 33.33%."
datetime: "2026-09-18T23:49:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299495670.md)
  - [en](https://longbridge.com/en/news/299495670.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299495670.md)
generator: "portal-rs"
---

# Alaunos Therapeutics surges 14% in after-hours on $1.1M financing deal

盘后交易时段，Alaunos Therapeutics(TCRT.US) 涨**13.83%**，现报**1.366 美元**。

公司宣布完成 112 万美元注册直接融资，以每股**1.46 美元**的价格发行**380,469 股**股份及最多**386,654 股**的预付认股权证，所得款项将用于营运资金。Dawson James Securities 担任配售代理，预计于 09/21/2026 前后完成交割。

公司同时修订章程细则，自 09/16/2026 起生效，将股东大会法定人数要求从多数投票权股份降至**三分之一（33.33%）**投票权，旨在为未来融资或并购等公司行动降低股东表决门槛。

财务方面，公司 2026 年上半年净亏损为**190 万美元**，无营业收入，现金储备仅**12 万美元**，月均烧钱率为**21 万美元**。研发支出因肥胖症项目增加**53%**至**81.4 万美元**，管理费用因运营规模缩减下降**28%**至**115 万美元**。主要候选药物 ALN1003 在临床前试验中持续取得进展。

### Related Stocks

- [TCRT.US](https://longbridge.com/en/quote/TCRT.US.md)

## Related News & Research

- [Alaunos Therapeutics Announces New Registered Direct Offering](https://longbridge.com/en/news/299813835.md)
- [Alaunos Therapeutics Enters Securities Purchase Agreement With Accredited Investors](https://longbridge.com/en/news/299810727.md)
- [Alaunos Therapeutics cuts stockholder meeting quorum requirement to one-third from majority](https://longbridge.com/en/news/299300336.md)
- [GRAPHIC-Take Five: It's Q4 already?](https://longbridge.com/en/news/300105805.md)
- [Alphabet vs. Tesla: One Mag 7 Stock Is a Winner, the Other Faces Too Many Questions](https://longbridge.com/en/news/300143230.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**